1Druker B J, Talpaz M, Resta D J, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia [J]. N Engl J Med, 2001, 344: 1031.
2Goldman J M, Melo J V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia [J]. N Engl J Med, 2001, 344: 1084.
3Druker B J, Sawyers C L, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome [J]. N Engl J Med, 2001, 344: 1038.
4Talpaz M, Silver R T, Druker B J, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid 1eukemia: results of a phase2 study [J]. Blood, 2002, 99: 1928.
5Sawyers C L, Hochhaus A, Feldman E, et al. Imatinib mesylate induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase Ⅱ study [J]. Blood, 2002, 99: 3530.
6Ottmann O G, Druker B J, Sawyers C L, et al. A phase Ⅱ study of imatinib Mesylate (Gleevec) in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemia [J]. Blood, 2002, 100: 1965.
7Sacchi S, Kantarjian H M, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients [J]. Cancer, 1999, 86: 2632.
8Walters R S, Kantarjian H M, Keating M J, et al. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron [J]. Cancer, 1987, 60: 1708.
9Copelan E A, Mcguire E A. The biology and treatment of acute 1ymphoblastic leukemia in adults [J]. Blood, 1995, 85: 1151.
10C1ift R A, Storb R. Marrow transplantation for CML: the Seattle experience [J]. Bone Marrow Transplant, 1996, 17(Suppl 3): S1.
5[2]Faded S,Kantarjian H M,Talpaz M.Chronic myelogenous leukemia[J].Oneology,1999,13:169
6[3]Druker B J,Talpaz M,Resta D J,et al.Efficacy and safety ofaspecific inhibitor of the BCR-ABL tyrosine kinase in chron icmyeloid leukemia[J].N Engl J Med,2001,344(14):1031
7[5]Kantarjian H,Sawyers C,Hochhaus A,et al.Hematologic and cytogenetic responses to imatinib mesylate in chronic my clogenous leukemia[J].N Engl J Med,2002,346(9):645
8[6]Thambi P,Sausville E A.STI571(imatinib mesylate):the tale of targeted therapy[J].Anticancer Drugs,2002,13(2):111
10DRUKER B J,TALPAZ M,RESTA D J,et al.Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia[J].N Engl J Med,2001,344(14):1031.
